文献速递病毒性肝炎

恩替卡韦与替诺福韦在高病毒载量初治慢性乙肝中的疗效与安全性比较

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
PubMed 文献 · Clin Microbiol Infect · 2017-02-09

该回顾性队列研究纳入419例核苷(酸)类似物初治、HBV DNA>6 log10 IU/mL的慢性乙肝患者(恩替卡韦313例,替诺福韦106例),经倾向评分匹配后比较两药长期疗效与安全性。结果显示两组3年病毒学应答、HBeAg清除/血清学转换及肝癌发生率均无显著差异,但替诺福韦与糖尿病是治疗期间急性肾损伤的独立因素。

要点

  • 高病毒载量初治CHB患者中,替诺福韦与恩替卡韦3年病毒学应答率无显著差异。
  • 两组HBeAg清除、血清学转换及肝癌发生率在队列和匹配人群中均无显著差异。
  • 替诺福韦和糖尿病是治疗期间急性肾损伤的独立因素,需监测肾功能。

核心结论

  • 在高病毒载量核苷(酸)类似物初治慢性乙肝患者中,替诺福韦与恩替卡韦疗效相似。
  • 替诺福韦治疗期间急性肾损伤发生率可能高于恩替卡韦。

研究设计与样本

  • 回顾性队列研究,纳入419例核苷(酸)类似物初治、HBV DNA>6 log10 IU/mL的慢性乙肝患者(恩替卡韦313例,替诺福韦106例)。
  • 采用倾向评分匹配,按年龄、基线HBV DNA水平和肝硬化状态,将106例替诺福韦组与212例恩替卡韦组匹配,并按HBeAg状态分层。

主要发现

  • 3年累积病毒学应答率:HBeAg阳性患者替诺福韦组96.4% vs 恩替卡韦组92.1%(p 0.26);HBeAg阴性患者98.2% vs 98.6%(p 0.64)。
  • 3年HBeAg清除率53.8% vs 47.4%(p 0.89),血清学转换率40.2% vs 41.3%(p 0.77)。
  • 肝癌发生率4% vs 2.7%(p 0.55),在队列和倾向评分匹配人群中均无显著差异。
  • HBV DNA>10^8 IU/mL亚组中,3年病毒学应答率90.9% vs 87.7%(p 0.13)。
  • 多因素分析显示HBeAg阴性、较低基线HBV DNA和HBsAg水平是病毒学应答的独立因素;年龄较大、较低基线HBV DNA、肝硬化及治疗12个月时AFP≥8 ng/mL与肝癌发生独立相关。

关键数值与推荐

  • 高病毒载量定义为HBV DNA>6 log10 IU/mL。
  • 替诺福韦和糖尿病是治疗期间急性肾损伤的独立因素。

临床怎么用

  • 高病毒载量初治慢性乙肝患者可选用替诺福韦或恩替卡韦,两者长期疗效相当。
  • 使用替诺福韦时,尤其合并糖尿病者,应监测急性肾损伤风险。
  • 治疗12个月AFP≥8 ng/mL、肝硬化、年龄较大及较低基线HBV DNA者需关注肝癌发生风险。

局限性

  • 回顾性队列设计可能存在选择偏倚和混杂因素。
  • 替诺福韦组样本量较小(106例),匹配后进一步减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aims of this study are to compare the long-term efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue (NA)-naive patients with chronic hepatitis B (CHB) with high hepatitis B virus (HBV) DNA (> 6 log10 IU/mL). METHODS: We recruited 419 NA-naive patients for analysis (313 entecavir, 106 tenofovir). We used propensity-score matching to match 106 patients in the tenofovir group with 212 patients in the entecavir group by age, baseline HBV DNA levels and cirrhosis after subgrouping by hepatitis B e antigen (HBeAg) status. RESULTS: There was no significant difference in 3-year cumulative rates of virological response (VR) (96.4% versus 92.1%, p 0.26 in HBeAg-positive or 98.2% versus 98.6%, p 0.64 in HBeAg-negative patients), HBeAg loss (53.8% versus 47.4%, p 0.89) or seroconversion (40.2% versus 41.3%, p 0.77), and hepatocellular carcinoma (HCC) development (4% versus 2.7%, p 0.55) between the tenofovir and entecavir groups in either cohort or propensity-score matching patients. In subgroup analysis of patients with HBV DNA >108 IU/mL, entecavir and tenofovir showed similar effectiveness in achieving VR (90.9% versus 87.7% at 3 years; p 0.13). Tenofovir and diabetes mellitus were independent factors for acute kidney injury during treatment. Multivariate analysis showed that HBeAg-negative status, and lower baseline HBV DNA and HBV surface antigen levels were independent factors for achieving VR. Older age, lower baseline HBV DNA levels, cirrhosis and α-fetoprotein ≥8 ng/mL at 12 months of treatment were independently associated with HCC development. CONCLUSIONS: Tenofovir and entecavir have similar effectiveness in NA-naive CHB patients with high viraemia. Tenofovir might have a higher incidence of acute kidney injury compared with entecavir during treatment.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Wu IT, Hu TH, Hung CH, et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect. 2017. PMID: 28189857. doi:10.1016/j.cmi.2017.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。